Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Accumulated Expenses (2020 - 2025)

Historic Accumulated Expenses for Bioventus (BVS) over the last 6 years, with Q3 2025 value amounting to $119.4 million.

  • Bioventus' Accumulated Expenses fell 718.82% to $119.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $119.4 million, marking a year-over-year decrease of 718.82%. This contributed to the annual value of $135.9 million for FY2024, which is 1342.63% up from last year.
  • Per Bioventus' latest filing, its Accumulated Expenses stood at $119.4 million for Q3 2025, which was down 718.82% from $113.7 million recorded in Q2 2025.
  • Bioventus' Accumulated Expenses' 5-year high stood at $146.8 million during Q3 2022, with a 5-year trough of $89.7 million in Q2 2021.
  • In the last 5 years, Bioventus' Accumulated Expenses had a median value of $118.9 million in 2023 and averaged $119.2 million.
  • As far as peak fluctuations go, Bioventus' Accumulated Expenses soared by 4908.43% in 2021, and later tumbled by 1879.72% in 2025.
  • Over the past 5 years, Bioventus' Accumulated Expenses (Quarter) stood at $131.5 million in 2021, then dropped by 15.14% to $111.6 million in 2022, then grew by 7.37% to $119.8 million in 2023, then grew by 13.43% to $135.9 million in 2024, then decreased by 12.09% to $119.4 million in 2025.
  • Its Accumulated Expenses was $119.4 million in Q3 2025, compared to $113.7 million in Q2 2025 and $103.3 million in Q1 2025.